PURPOSE: To determine whether simvastatin is able to inhibit inflammation in trinitrobenzene sulfonic acid (TNBS)-induced or oxazalone (OXA)-induced colitis. RESULTS: In the prophylactic protocol, simvastatin dose-dependently suppressed the decrease in body weight and inflammatory grade of TNBS-treated mice. In contrast, in the therapeutic protocol, no significant difference in body weight reduction was observed between simvastatin-treated and control mice. IFN-gamma release from LP cells was significantly suppressed in mice receiving high-dose simvastatin in the prophylactic protocol. In contrast to TNBS colitis, even high-dose prophylactic simvastatin had no suppressive effects on either weight reduction or the inflammatory grade in OXA colitis. CONCLUSION: Our results indicate that simvastatin negatively regulates inflammation in TNBS-induced colitis, but not in OXA-induced colitis. In TNBS-induced colitis, simvastatin suppressed the Th1-polarized immune response. Our findings suggest that simvastatin has potential effects as a therapeutic agent in human inflammatory bowel disease, particularly Crohn's disease.
雑誌名
Digestive diseases and sciences
巻
53
号
7
ページ
1869 - 1875
発行年
2008-07
出版者
Springer Netherlands
ISSN
01632116
EISSN
1573-2568
書誌レコードID
AA00161107
PubMed番号
18049901
DOI
10.1007/s10620-007-0102-0
権利
c Springer Science+Business Media, LLC 2007
The original publication is available at www.springerlink.com
著者版フラグ
author
引用
Digestive diseases and sciences, 53(7), pp.1869-1875; 2008
Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis.
DDS53_1869.pdf
(1.72MB)
NAOSITEについて